The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

Mon, 13th Jan 2020 10:34

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.

----------

FTSE 100 - WINNERS

----------

Taylor Wimpey, up 2.8%. Peel Hunt raised the housebuilder to Add from Hold.

----------

Hikma Pharmaceuticals, up 2.1%. The drugmaker said it has signed an exclusive licensing and distribution agreement with Italian pharma firm Chiesi Farmaceutici. The agreement provides Hikma with exclusive rights to commercialise 11 of Chiesi's products in Egypt, including currently marketed and pipeline products. Hikma noted this agreement builds on the existing partnership between the pair in Morocco.

----------

Halma, up 2.0%. Goldman Sachs raised the smoke detector maker to Buy from Neutral.

----------

Centrica, up 1.8%. UBS raised the British Gas parent to Buy from Neutral.

----------

FTSE 100 - LOSERS

----------

St James's Place, down 1.0%. Credit Suisse downgraded the wealth manager to Underperform from Neutral.

----------

FTSE 250 - WINNERS

----------

Spirent Communications, up 16%. The telecommunications network testing firm said it was able to continue its good momentum into the fourth quarter of 2019 and expects full-year profit to exceed market expectations. Spirent said it was able to secure a number of "important" contract wins in the final three months of 2019, resulting in 2019 total group revenue rising by 5.5% versus the year before to USD503 million. The company also expects its adjusted operating profit to be between USD91 million and USD93 million - which would represent a rise of between 18% and 21% on the USD77.1 million reported in 2018. "Over the medium term we expect to continue to deliver mid-single digit revenue growth with a focus on increasing recurring revenue streams to enhance the group's visibility and effective investment in our technical platforms to drive ongoing performance," Chief Executive Eric Updyke said.

----------

Pennon Group, up 7.5%. The Daily Telegraph reported that the water company's Viridor waste management arm is set to be put up for sale. Citing "City sources", the newspaper said Pennon rejected a bid from US private equity fund KKR early in 2019 that was an attempt to jump-start the sale process for Viridor. Now, banks Morgan Stanley and Barclays have been appointed to run the process at a valuation for Viridor of GBP4 billion, the newspaper said.

----------

Savills, up 5.6%. The estate agent said its annual performance will be at the upper end of expectations due to an "excellent" performance in the UK, significant growth in the US and a strong performance from the Savills Investment Management arm. Savills said despite challenges such as Brexit, and political unrest in Hong Kong contributing to lower volumes of activity, "the strength of Savills positions in both markets contributed to a resilient performance through increased market share". Savills Investment Management also performed ahead of expectations, benefiting from performance fees on "certain products". Looking to the year ahead, Savills noted global investor demand for secure income, restricted supply and expectations of continued low interest rates suggests that the medium and long term dynamics of the UK real estate market should remain largely positive.

----------

Avast, up 3.5%. JPMorgan upgraded the antivirus software maker to Overweight from Neutral.

----------

FTSE 250 - LOSERS

----------

Just Group, down 2.6%. Credit Suisse cut the retirement financial products provider to Underperform from Neutral.

----------

Mitchells & Butlers, down 2.2%. JPMorgan downgraded the pub and restaurant operator to Neutral from Overweight.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Verona Pharma, up 53%. The pharmaceutical company said its Phase 2b clinical trial of nebulized Ensifentrine met its primary endpoint. The four-week Phase 2b trial of the drug in moderate to severe chronic obstructive pulmonary disease patients improved lung function at week four of the treatment. In the trial, the drug was administered twice daily in combination with tiotropium, a treatment used in the management of chronic obstructive pulmonary disease and asthma.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

City Pub, down 9.1%. The pub operator warned profit will miss market expectations due to "subdued" trading over the key Christmas period. In its financial year ended December 29, the southern England and Wales-focused pub owner said it performed well, with revenue rising 31% to GBP59.8 million. Like-for-like sales were up 1.7%, and City Pub Group said it is pleased with this performance. However, a number of one-off factors in the last quarter of its year held back fourth-quarter performance. As a result, adjusted earnings before interest, tax, depreciation, and amortisation for the year is now expected to be slightly below market expectations, between GBP9.1 million and GBP9.2 million. This would still be an approximate 15% rise year-on-year. City Pub also said the 2018 festive season was a very strong one, providing a tough comparable for the recently ended season.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
2 Mar 2018 15:01

BUZZ-Verona Pharma: Soars on positive data from mid-stage study

** British drug developer's U.S.-listed shares up 16 pct at $16.44 in morning trade - second highest gainer amongst Nasdaq-listed companies ** data a

Read more
18 Jan 2017 10:13

Verona Pharma Proposes Share Consolidation Amid Plans To List In US (ALLISS)

Read more
26 Sep 2016 09:39

Verona Pharma appoints sector veteran Morgan as CFO

(ShareCast News) - AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug. Chartered accountant Morgan has 25 years' financial experience and was previously c

Read more
13 Sep 2016 12:04

Verona Pharma makes progress on new respiratory drug

(ShareCast News) - Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554". The company's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulized maintenance tr

Read more
20 Jun 2016 15:02

UK Shareholder Meetings Calendar - Next 7 Days

Read more
20 Jun 2016 12:50

Verona Pharma secures funding for drug trial

(ShareCast News) - Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed. Net proceeds from the placing with new

Read more
20 Jun 2016 11:06

LONDON MARKET MIDDAY: Receding Brexit Fear Lifts Stocks And Pound

Read more
20 Jun 2016 09:40

WINNERS & LOSERS SUMMARY: Cat Allergy Disappointment Sinks Circassia

Read more
17 Jun 2016 16:09

Verona Pharma To Raise GBP44.7 Million In Share Placing (ALLIS)

Read more
3 Jun 2016 12:52

Verona Pharma's shares fall as higher R&D costs widen FY loss

(ShareCast News) - Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling. Chief executive Jan-Anders Karlsson said Verona had made substantial clinical progress with its

Read more
3 Jun 2016 06:59

Verona Pharma Loss Widens On Higher Research And Development Costs

Read more
10 May 2016 08:11

Verona Pharma Gets Positive Results From COPD Treatment Study

Read more
15 Mar 2016 10:35

Verona Pharma excites with asthma trial results

(ShareCast News) - Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD). Tests among asthma patients found the inhaled drug, which has both bronchodilator and anti-inflammatory properties in the same active molecu

Read more
21 Jan 2016 13:31

DIRECTOR DEALINGS: Verona Pharma Chairman Ups Interest

Read more
11 Jan 2016 08:45

Verona Pharma Chief Financial Officer Biresh Roy Leaving Company

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.